Human Irisin Concentration in Sarcopenia

Irisin has been identified as a novel myokine that drives brown-fat-like conversion of white adipose tissue. In this cross-sectional study, the researches investigated whether serum irisin levels are decreased in patients with sarcopenia compared with control subjects with normal muscle mass, and assessed the association between serum irisin levels and various metabolic parameters.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Sarcopenia Atrophy Muscular Atrophy Nervous System Diseases Neurologic Manifestations Neuromuscular Manifestations Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

20 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Korea University Guro Hospital

Seoul, South Korea

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

20<age<80
apparently healthy subjects

Exclusion criteria

a history of cardiovascular disease
diabetes
stage 2 hypertension
malignancy
severe renal or hepatic disease

Treatment and study plan

Primary outcomes

Serum concentration of irisin in the subjects with sarcopenia

Time frame: 12 week

Secondary outcomes

The relationship of serum irisin levels with lipid profiles

Time frame: 12 week
The relationship of serum irisin levels with skeletal muscle mass index

Time frame: 12 wks

Sponsors and collaborators

Lead sponsor

Korea University

Other

Registry information

Important dates

Study start: 2009
Primary completion: 2011
Study completion: 2011
First posted: Jun 11, 2013
Registry last updated: Jun 11, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed